Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Vlachopoulos, C; Xaplanteris, P; Aboyans, V; Brodmann, M; Cífková, R; Cosentino, F; De Carlo, M; Gallino, A; Landmesser, U; Laurent, S; Lekakis, J; Mikhailidis, DP; Naka, KK; Protogerou, AD; Rizzoni, D; Schmidt-Trucksäss, A; Van Bortel, L; Weber, T; Yamashina, A; Zimlichman, R; Boutouyrie, P; Cockcroft, J; O'Rourke, M; Park, JB; Schillaci, G; Sillesen, H; Townsend, RR.
The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society.
Atherosclerosis. 2015; 241(2):507-532 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Brodmann Marianne
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
While risk scores are invaluable tools for adapted preventive strategies, a significant gap exists between predicted and actual event rates. Additional tools to further stratify the risk of patients at an individual level are biomarkers. A surrogate endpoint is a biomarker that is intended as a substitute for a clinical endpoint. In order to be considered as a surrogate endpoint of cardiovascular events, a biomarker should satisfy several criteria, such as proof of concept, prospective validation, incremental value, clinical utility, clinical outcomes, cost-effectiveness, ease of use, methodological consensus, and reference values. We scrutinized the role of peripheral (i.e. not related to coronary circulation) noninvasive vascular biomarkers for primary and secondary cardiovascular disease prevention. Most of the biomarkers examined fit within the concept of early vascular aging. Biomarkers that fulfill most of the criteria and, therefore, are close to being considered a clinical surrogate endpoint are carotid ultrasonography, ankle-brachial index and carotid-femoral pulse wave velocity; biomarkers that fulfill some, but not all of the criteria are brachial ankle pulse wave velocity, central haemodynamics/wave reflections and C-reactive protein; biomarkers that do no not at present fulfill essential criteria are flow-mediated dilation, endothelial peripheral arterial tonometry, oxidized LDL and dysfunctional HDL. Nevertheless, it is still unclear whether a specific vascular biomarker is overly superior. A prospective study in which all vascular biomarkers are measured is still lacking. In selected cases, the combined assessment of more than one biomarker may be required. Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Aging -
Ankle Brachial Index -
Biomarkers - blood
Biomarkers - metabolism
C-Reactive Protein - metabolism
Cardiology - standards
Cardiovascular Diseases - blood
Cardiovascular Diseases - diagnosis
Carotid Arteries - diagnostic imaging
Carotid Intima-Media Thickness -
Cost-Benefit Analysis -
Decision Making -
Europe -
Hemodynamics -
Humans -
Primary Prevention -
Research Design -
Risk -
Secondary Prevention -
Societies, Medical -
Treatment Outcome -
Ultrasonography -
Vascular Stiffness -

Find related publications in this database (Keywords)
Vascular biomarkers
Carotid ultrasonography
Ankle-brachial index
Arterial stiffness
Central haemodynamics
Wave reflections
Endothelial function
Circulating biomarkers
© Meduni Graz Impressum